Aclaris Therapeutics, Inc. (ACRS)

Price$4.34

Value ScoreD

Growth ScoreC

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)72.87%

Price vs S&P 500 (4W)-1.80%

VGM Score49.35

Market Capitalization$614.52M

All Metrics

Book Value / Share (Quarterly)$1.03

P/TBV (Annual)0.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-35.93%

Cash Flow / Share (Quarterly)$-0.37

Price vs S&P 500 (YTD)40.23%

Gross Margin (TTM)9.69%

Net Profit Margin (TTM)-832.58%

EPS (TTM)$-0.56

10-Day Avg Trading Volume0.93M

EPS Excl Extra (TTM)$-0.56

Revenue Growth (5Y)3.85%

EPS (Annual)$-0.53

ROI (Annual)-62.98%

Gross Margin (Annual)6.93%

Net Profit Margin (5Y Avg)-690.91%

Cash / Share (Quarterly)$0.75

Revenue Growth QoQ (YoY)37.18%

ROA (Last FY)-40.46%

Revenue Growth TTM (YoY)-52.94%

EBITD / Share (TTM)$-0.64

ROE (5Y Avg)-58.84%

Operating Margin (TTM)-961.91%

Cash Flow / Share (Annual)$-0.40

P/B Ratio4.28x

P/B Ratio (Quarterly)3.15x

Net Income / Employee (Annual)$-940,900

EV / Revenue (TTM)70.02x

ROA (TTM)-38.49%

EPS Incl Extra (Annual)$-0.53

Current Ratio (Annual)3.36x

Quick Ratio (Quarterly)4.03x

3-Month Avg Trading Volume1.70M

52-Week Price Return211.64%

Revenue / Employee (TTM)$121,300

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)78.52x

Asset Turnover (Annual)0.05x

52-Week High$5.15

Operating Margin (5Y Avg)-734.98%

EPS Excl Extra (Annual)$-0.53

CapEx CAGR (5Y)15.97%

Tangible BV CAGR (5Y)-5.47%

26-Week Price Return88.80%

Quick Ratio (Annual)3.36x

13-Week Price Return45.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.03x

Enterprise Value$585.86M

Revenue / Share Growth (5Y)-15.95%

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)0.46%

Revenue / Employee (Annual)$113,400

Pretax Margin (Annual)-829.58%

Cash / Share (Annual)$0.75

3-Month Return Std Dev68.68%

Gross Margin (5Y Avg)31.55%

Net Income / Employee (TTM)$-1,009,600

ROE (Last FY)-62.98%

EPS Basic Excl Extra (Annual)$-0.53

Receivables Turnover (TTM)3.30x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.56

Receivables Turnover (Annual)2.66x

ROI (TTM)-55.89%

P/S Ratio (TTM)73.45x

Pretax Margin (5Y Avg)-691.15%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$2.21

Price vs S&P 500 (52W)183.44%

Year-to-Date Return51.16%

5-Day Price Return0.66%

EPS Normalized (Annual)$-0.53

ROA (5Y Avg)-43.11%

Net Profit Margin (Annual)-829.58%

Month-to-Date Return4.84%

Cash Flow / Share (TTM)$-1.65

EBITD / Share (Annual)$-0.62

Operating Margin (Annual)-975.91%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-58.84%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.56

P/TBV (Quarterly)0.47x

P/B Ratio (Annual)3.16x

Inventory Turnover (TTM)8.60x

Pretax Margin (TTM)-832.58%

Book Value / Share (Annual)$0.86

Price vs S&P 500 (13W)35.62%

Beta0.81x

Revenue / Share (TTM)$0.07

ROE (TTM)-55.89%

52-Week Low$1.34

vGradeD

gGradeC

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.15est. -0.16

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.21

4.27

4.31

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACRSAclaris Therapeutics, Inc.	D	C	A	$4.34
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing immuno-inflammatory disease therapies, including candidates Zunsemetinib (an Oral MK2 Inhibitor), Lepzacitinib, ATI-2138 (an ITJ Inhibitor), and ATI-052. The company also operates a contract research segment providing laboratory services, though therapeutics drives the majority of revenue.